Fig. 1: CH-alterations and risk of hematologic malignancies.
From: Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk
A Increased risk of hematologic malignancy in the UK Biobank cohort with or without mCAs, DNMT3A/JAK2/TET2/TP53. B Increased risk of hematologic malignancy in the BioVU cohort with or without mCAs, DNMT3A/JAK2, and both.
